Zacks Research Has Pessimistic Outlook of Amgen Q1 Earnings

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Zacks Research decreased their Q1 2025 earnings estimates for Amgen in a research report issued to clients and investors on Friday, October 25th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $4.69 for the quarter, down from their previous estimate of $4.79. The consensus estimate for Amgen’s current full-year earnings is $19.49 per share. Zacks Research also issued estimates for Amgen’s Q2 2025 earnings at $5.07 EPS, Q1 2026 earnings at $4.84 EPS, Q2 2026 earnings at $5.20 EPS, Q3 2026 earnings at $5.27 EPS and FY2026 earnings at $20.75 EPS.

A number of other analysts also recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 target price on shares of Amgen in a research report on Tuesday, October 22nd. Bank of America lifted their target price on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Robert W. Baird reaffirmed an “underperform” rating and set a $215.00 price target on shares of Amgen in a research report on Wednesday, September 25th. Wells Fargo & Company downgraded Amgen from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. Finally, Morgan Stanley dropped their price objective on Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $332.55.

Amgen Price Performance

Shares of AMGN opened at $317.17 on Monday. The business has a 50-day moving average of $325.27 and a 200-day moving average of $314.44. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The company has a market capitalization of $170.14 billion, a price-to-earnings ratio of 45.31, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. Amgen has a 1 year low of $249.70 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same period in the prior year, the business earned $5.00 earnings per share. The firm’s revenue for the quarter was up 20.1% on a year-over-year basis.

Institutional Trading of Amgen

Institutional investors and hedge funds have recently modified their holdings of the business. Strategic Financial Concepts LLC bought a new position in Amgen in the 2nd quarter valued at $26,000. Hershey Financial Advisers LLC purchased a new position in shares of Amgen in the 2nd quarter worth about $30,000. nVerses Capital LLC bought a new position in Amgen during the second quarter valued at about $31,000. Bbjs Financial Advisors LLC purchased a new stake in Amgen during the second quarter worth about $33,000. Finally, Matrix Trust Co bought a new stake in Amgen in the third quarter worth about $36,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 2.84%. Amgen’s dividend payout ratio (DPR) is 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.